Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
88.63
+0.88 (1.00%)
At close: Nov 20, 2024, 4:00 PM
88.40
-0.23 (-0.26%)
Pre-market: Nov 21, 2024, 5:09 AM EST
Gilead Sciences Employees
Gilead Sciences had 18,000 employees as of December 31, 2023. The number of employees increased by 1,000 or 5.88% compared to the previous year.
Employees
18,000
Change (1Y)
1,000
Growth (1Y)
5.88%
Revenue / Employee
$1,572,167
Profits / Employee
$7,000
Market Cap
110.46B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
Dec 31, 2021 | 14,400 | 800 | 5.88% |
Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
Jan 31, 2015 | 7,000 | 900 | 14.75% |
Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
Jan 31, 2013 | 5,000 | 500 | 11.11% |
Jan 31, 2012 | 4,500 | 500 | 12.50% |
Jan 31, 2011 | 4,000 | 148 | 3.84% |
Jan 31, 2010 | 3,852 | 411 | 11.94% |
Jan 31, 2009 | 3,441 | 462 | 15.51% |
Jan 31, 2008 | 2,979 | 464 | 18.45% |
Jan 31, 2007 | 2,515 | 615 | 32.37% |
Jan 31, 2006 | 1,900 | 246 | 14.87% |
Feb 28, 2005 | 1,654 | 229 | 16.07% |
Feb 27, 2004 | 1,425 | 175 | 14.00% |
Feb 28, 2003 | 1,250 | 250 | 25.00% |
Feb 28, 2002 | 1,000 | 150 | 17.65% |
Feb 28, 2001 | 850 | 90 | 11.84% |
Dec 31, 1999 | 760 | 467 | 159.39% |
Dec 31, 1998 | 293 | 4 | 1.38% |
Dec 31, 1997 | 289 | 41 | 16.53% |
Dec 31, 1996 | 248 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
HCA Healthcare | 310,000 |
Elevance Health | 104,900 |
Medtronic | 95,000 |
Pfizer | 88,000 |
Sanofi | 86,088 |
The Cigna Group | 72,500 |
Boston Scientific | 48,000 |
Bristol-Myers Squibb Company | 34,100 |
GILD News
- 20 hours ago - Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript) - Seeking Alpha
- 5 days ago - Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease - Benzinga
- 5 days ago - Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis - Business Wire
- 7 days ago - Gilead Sciences to close Seattle office; shutdown impacts 72 employees - GeekWire
- 7 days ago - Gilead Prices $3.5 Billion of Senior Unsecured Notes - Business Wire
- 8 days ago - Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow - Business Wire
- 9 days ago - Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline - Business Wire
- 12 days ago - Gilead Sciences: Finally Some Real Momentum - Seeking Alpha